HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 11-19-2010, 12:42 PM   #1
Rich66
Senior Member
 
Rich66's Avatar
 
Join Date: Feb 2008
Location: South East Wisconsin
Posts: 3,431
Xl184

http://www.exelixis.com/pipeline/xl184

XL184 is a small molecule designed to inhibit multiple receptor tyrosine kinases, specifically MET and VEGFR2. MET is a receptor tyrosine kinase that plays key roles in cellular proliferation, migration, and invasion as well as angiogenesis1. These biological processes contribute to the transformation, progression, survival and metastasis of cancer cells1. The MET pathway is frequently activated in tumors through MET amplification, mutation, and overexpression, as well as through overexpression of its ligand HGF1. Expression of VEGF has been observed in a variety of cancers and has been associated with the stimulation and growth of new blood vessels to support the tumor2,3. MET and VEGFR2 are important driving forces in angiogenesis, implicated in the ability of tumors to overcome hypoxia following angiogenesis inhibition4,5.

  1. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 2005; 225(1):1-26.
  2. Sandler A. Bevacizumab in non-small cell lung cancer. Clin Cancer Res. 2007; 13 (15 Suppl): 4613s-4616s.
  3. Heath VL and Bicknell R. Anticancer strategies involving the vasculature. Nat Rev Clin Oncol. 2009; Jul;6(7):395-404.
  4. You WK and McDonald DM. The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis. BMB Reports. 2008; 41:833–839.
  5. Schmidt C. Why do tumors become resistant to antiangiogenesis drugs? J. Natl. Cancer. Inst. 2009;101:1530–1532.

Solid tumor STUDY
http://www.clinicaltrials.gov/ct2/sh...ow_locs=Y#locn


Exelixis Shares Soar on Cancer Results

Luke Timmerman 11/18/10

LINK

Exelixis (NASDAQ: EXEL), the South San Francisco-based developer of cancer drugs, saw its shares climb 32 percent to $6.23 today after reporting on clinical trial results for its lead product candidate against prostate cancer. The company reported that 19 out of 20 patients who got its experimental XL184 treatment had at least partial clearance of lesions on their bones where the cancer had spread. The findings were released at the EORTC-NCI-AACR meeting in Berlin, Germany. Xconomy reported on what this clinical trial data means to Exelixis in an in-depth feature story last month.
__________________

Mom's treatment history (link)
Rich66 is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 09:02 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter